Patents by Inventor Monica L. Guzman
Monica L. Guzman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210332062Abstract: The present disclosure provides SL and SL derivatives comprising a polar substituent adjacent to the lactone ring. Additionally, the present disclosure provides methods of using the SL and SL derivatives to inhibit the growth of leukemic cancer cells.Type: ApplicationFiled: May 28, 2021Publication date: October 28, 2021Applicant: Board of Trustees of the University of ArkansasInventors: Monica L. Guzman, Cesar M. Compadre, Paola E. Ordonez, Mariano Martinez, Michael J. Balick, Darin E. Jones, Flavio G. Gaudio
-
Patent number: 11059800Abstract: The present invention provides dehydroleucodine derivatives. In particular, the present invention provides amine derivatives of dehydroleucodine and methods of using dehydroleucodine and the amine derivatives of dehydroleucodine to inhibit the growth of cancer cells.Type: GrantFiled: February 22, 2019Date of Patent: July 13, 2021Assignees: Universidad Tecnica Particular De Loja, Cornell University, BioVentures, LLCInventors: Cesar M. Compadre, Paola E. Ordonez, Monica L. Guzman, Darin E. Jones, Omar Malagon, Giovanni Vidari, Peter Crooks
-
Patent number: 11021488Abstract: The present disclosure provides SL and SL derivatives comprising a polar substituent adjacent to the lactone ring. Additionally, the present disclosure provides methods of using the SL and SL derivatives to inhibit the growth of leukemic cancer cells.Type: GrantFiled: July 26, 2019Date of Patent: June 1, 2021Assignees: Board of Trustees of the University of Arkansas, BioVentures, LLC, Cornell University, New York Botanical GardenInventors: Monica L. Guzman, Cesar M. Compadre, Paola E. Ordonez, Mariano Martinez, Michael J. Balick, Darin E. Jones, Flavio G. Gaudio
-
Publication number: 20200222452Abstract: A method for treating leukemia is disclosed. The method comprises administering to a subject with leukemia an effective amount of a pharmaceutical composition comprising a naked iron oxide nanoparticle, wherein the composition is not loaded with an active agent. Also disclosed is a method for treating cancer. The method comprises administering an effective amount of a pharmaceutical composition comprising a metal oxide nanoparticle comprising a polymeric coating over a metal oxide core, wherein the nanoparticle is loaded with a reactive oxygen species (ROS)-inducing agent.Type: ApplicationFiled: September 11, 2019Publication date: July 16, 2020Applicants: Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell UniversityInventors: Jan GRIMM, Monica L. GUZMAN, Charalambos KAITTANIS
-
Publication number: 20190345167Abstract: The present disclosure provides SL and SL derivatives comprising a polar substituent adjacent to the lactone ring. Additionally, the present disclosure provides methods of using the SL and SL derivatives to inhibit the growth of leukemic cancer cells.Type: ApplicationFiled: July 26, 2019Publication date: November 14, 2019Applicant: Board of Trustees of the University of ArkansasInventors: Monica L. Guzman, Cesar M. Compadre, Paola E. Ordonez, Mariano Martinez, Michael J. Balick, Darin E. Jones, Flavio G. Gaudio
-
Publication number: 20190185442Abstract: The present invention provides dehydroleucodine derivatives. In particular, the present invention provides amine derivatives of dehydroleucodine and methods of using dehydroleucodine and the amine derivatives of dehydroleucodine to inhibit the growth of cancer cells.Type: ApplicationFiled: February 22, 2019Publication date: June 20, 2019Inventors: Cesar M. Compadre, Paola E. Ordonez, Monica L. Guzman, Darin E. Jones, Omar Malagon, Giovanni Vidari, Peter Crooks
-
Publication number: 20180319815Abstract: The present disclosure provides SL and SL derivatives comprising a polar substituent adjacent to the lactone ring. Additionally, the present disclosure provides methods of using the SL and SL derivatives to inhibit the growth of leukemic cancer cells.Type: ApplicationFiled: November 3, 2016Publication date: November 8, 2018Applicant: Board of Trustees of the University of ArkansasInventors: Monica L. Guzman, Cesar M. Compadre, Paola E. Ordonez, Mariano Martinez, Michael J. Balick, Darin E. Jones, Flavio G. Gaudio
-
Publication number: 20180296595Abstract: A method for treating leukemia is disclosed. The method comprises administering to a subject with leukemia an effective amount of a pharmaceutical composition comprising a naked iron oxide nanoparticle, wherein the composition is not loaded with an active agent. Also disclosed is a method for treating cancer. The method comprises administering an effective amount of a pharmaceutical composition comprising a metal oxide nanoparticle comprising a polymeric coating over a metal oxide core, wherein the nanoparticle is loaded with a reactive oxygen species (ROS)-inducing agent.Type: ApplicationFiled: September 9, 2016Publication date: October 18, 2018Applicants: Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell UniversityInventors: Jan GRIMM, Monica L. GUZMAN, Charalambos KAITTANIS
-
Patent number: 9555137Abstract: The disclosure provides evidence that the abundance of this particular “oncogenic HSP90” species, which is not dictated by HSP90 expression alone, predicts for sensitivity to HSP90 inhibition therapy, and thus is a biomarker for HSP90 therapy. The disclosure also provides evidence that identifying and measuring the abundance of this oncogenic HSP90 species in tumors predicts of response to HSP90 therapy. “Oncogenic HSP90” is defined herein as the HSP90 fraction that represents a cell stress specific form of chaperone complex, that is expanded and constitutively maintained in the tumor cell context, and that may execute functions necessary to maintain the malignant phenotype. Such roles are not only to regulate the folding of overexpressed (i.e. HER2), mutated (i.e. mB-Raf) or chimeric proteins (i.e. Bcr-Abl), but also to facilitate scaffolding and complex formation of molecules involved in aberrantly activated signaling complexes (i.e. STATS, BCL6).Type: GrantFiled: July 6, 2012Date of Patent: January 31, 2017Assignees: Sloan-Kettering Institute for Cancer Research, Cornell UniversityInventors: Gabriela Chiosis, Tony Taldone, Mary L. Alpaugh, Erica M. Gomes-Dagama, Monica L. Guzman, Hongliang Zong
-
Publication number: 20160176839Abstract: The present invention provides dehydroleucodine derivatives. In particular, the present invention provides amine derivatives of dehydroleucodine and methods of using dehydroleucodine and the amine derivatives of dehydroleucodine to inhibit the growth of cancer cells.Type: ApplicationFiled: July 11, 2014Publication date: June 23, 2016Inventors: Cesar M. Compadre, Paola E. Ordonez, Monica L. Guzman, Darin E. Jones, Omar Malagon, Giovanni Vidari, Peter Crooks
-
Publication number: 20140242602Abstract: The disclosure provides evidence that the abundance of this particular “oncogenic HSP90” species, which is not dictated by HSP90 expression alone, predicts for sensitivity to HSP90 inhibition therapy, and thus is a biomarker for HSP90 therapy. The disclosure also provides evidence that identifying and measuring the abundance of this oncogenic HSP90 species in tumors predicts of response to HSP90 therapy. “Oncogenic HSP90” is defined herein as the HSP90 fraction that represents a cell stress specific form of chaperone complex, that is expanded and constitutively maintained in the tumor cell context, and that may execute functions necessary to maintain the malignant phenotype. Such roles are not only to regulate the folding of overexpressed (i.e. HER2), mutated (i.e. mB-Raf) or chimeric proteins (i.e. Bcr-Abl), but also to facilitate scaffolding and complex formation of molecules involved in aberrantly activated signaling complexes (i.e. STATS, BCL6).Type: ApplicationFiled: July 6, 2012Publication date: August 28, 2014Applicants: CORNELL UNIVERSITY, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Gabriela Chiosis, Tony Taldone, Mary L. Alpaugh, Erica M. Gomes-Dagama, Monica L. Guzman, Hongliang Zong